Rhythm Pharmaceuticals, Inc.
RYTM
$50.97
$0.731.45%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 25.80% | 14.35% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 25.80% | 14.35% | |||
| Cost of Revenue | -1.07% | 29.89% | |||
| Gross Profit | 29.30% | 12.60% | |||
| SG&A Expenses | 7.78% | -2.85% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 7.71% | 10.90% | |||
| Operating Income | 5.99% | -8.42% | |||
| Income Before Tax | 1.37% | -38.40% | |||
| Income Tax Expenses | 73.84% | -171.82% | |||
| Earnings from Continuing Operations | 0.80% | -35.27% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 0.80% | -35.27% | |||
| EBIT | 5.99% | -8.42% | |||
| EBITDA | 6.04% | -8.51% | |||
| EPS Basic | 1.36% | -33.54% | |||
| Normalized Basic EPS | 1.96% | -37.90% | |||
| EPS Diluted | 1.36% | -33.54% | |||
| Normalized Diluted EPS | 1.96% | -37.90% | |||
| Average Basic Shares Outstanding | 0.61% | 0.34% | |||
| Average Diluted Shares Outstanding | 0.61% | 0.34% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
